Skip to main content
ABIVAX logo

ABIVAX — Investor Relations & Filings

Ticker · ABVX ISIN · FR0012333284 LEI · 969500D8TMNB184OJU95 PA Manufacturing
Open in API
Filings indexed 872 across all filing types
Latest filing 2024-07-23 Capital/Financing Update
Country FR France
Listing PA ABVX

About ABIVAX

https://www.abivax.com

Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.

Recent filings

Filing Released Lang Actions
ABIVAX: Bilan semestriel du contrat de liquidité au 30 juin 2024.
Capital/Financing Update Classification · 1% confidence The document is titled "Bilan semestriel du contrat de liquidité au 30 juin 2024" (Semi-annual statement of the liquidity contract as of June 30, 2024). It details the status and transactions (purchases and sales) conducted under a liquidity contract (market making agreement) for the first half of 2024. This type of disclosure, which reports on the activity of a share buyback/liquidity provision program, directly relates to the company's own shares. Among the provided definitions, 'Transaction in Own Shares' (Code: POS) is the most appropriate fit, as liquidity contracts are mechanisms for managing share price stability, often involving the company or its designated agent trading the company's own stock. It is not a general financing update (CAP) or a standard earnings report (ER/IR).
2024-07-23 French
Franchissement de seuil
Major Shareholding Notification Classification · 1% confidence The document is titled "Déclaration de franchissement de seuil (article L. 233-7 du code de commerce)" which translates to 'Declaration of crossing a threshold (Article L. 233-7 of the Commercial Code)'. This type of filing in France (often submitted to the AMF, mentioned in the text) relates to significant changes in share ownership, specifically when an investor crosses ownership thresholds (like 5%). This directly corresponds to the definition of a Major Shareholding Notification (MRQ), which covers 'Notification of changes in significant share ownership levels (crossing thresholds)'. The document details the date the threshold was crossed (Feb 28, 2023) and the resulting ownership percentage (7.38% of capital, 6.41% of voting rights).
2024-07-22 French
Abivax fournit une mise à jour opérationnelle et fait le point sur son programme clinique clé
Earnings Release Classification · 1% confidence The document is a press release dated July 15, 2024, providing updates on clinical trial progress (ABTECT Phase 3 for Ulcerative Colitis, ENHANCE-CD Phase 2b for Crohn's Disease), financial position (cash runway), R&D pipeline milestones, and significant management/board changes (new Chairwoman, new Chief Medical Officer, new Chief Strategy Officer). This content structure—combining operational updates, financial status, and governance changes in a formal announcement format—is characteristic of an Earnings Release (ER) or a general operational update. Since it provides key highlights and updates rather than the full, detailed financial statements of a quarterly report (IR) or the comprehensive annual review (10-K), and it is not a transcript (CT) or a presentation (IP), the most fitting category is Earnings Release (ER), as these releases often serve as the primary vehicle for communicating period-end financial health and operational milestones simultaneously. It is not a simple announcement of a report (RPA) because it contains substantial new information, not just a pointer to an attached document. Q3 2024
2024-07-15 French
Abivax Provides Operational and Key Program Update
Regulatory Filings Classification · 1% confidence The document is titled "Abivax Provides Operational and Key Program Update" and is dated July 15, 2024. It details progress on clinical trials (ABTECT Phase 3), financial runway, and significant leadership changes (new Chair, CMO, CSO). This content structure—combining operational/pipeline updates with executive changes—is characteristic of a press release announcing key company developments, often issued outside of mandatory quarterly/annual filings. Since it is not a full financial report (10-K or IR), nor a transcript (CT), nor a specific regulatory filing like DIRS or DIV, it best fits the category for general corporate news updates. Given the content focuses heavily on operational progress and leadership appointments, it is most accurately classified as an Earnings Release (ER) if it were tied to a reporting period, or more generally, a Regulatory Filing (RNS) if it's a broad update not fitting other specific categories. However, the content is a comprehensive operational update that includes financial highlights and management changes, which often accompanies or substitutes for a formal Earnings Release (ER) when providing key highlights. Since it is a detailed update covering multiple facets (pipeline, leadership, cash position) released via EQS-News, it functions as a major corporate announcement. Given the options, 'ER' (Earnings Release) is often used for these comprehensive operational/financial updates, even if not strictly quarterly results, or 'RNS' as a general regulatory announcement. Because it provides key financial highlights (cash runway) alongside operational milestones, ER is a strong candidate, but since it's explicitly an 'Operational and Key Program Update' rather than a formal 'Earnings Release' focused solely on P&L, RNS (Regulatory Filings/General Announcement) is the safest fallback for a non-standard, yet material, corporate update. Upon review, the content is very similar to what many biotech firms issue as an 'Operational Update' which often serves the function of an ER without being the formal earnings release document itself. Given the mix of operational, financial, and management news, and the lack of a specific 'Operational Update' code, RNS is the most appropriate general classification for a material, non-standard announcement.
2024-07-15 English
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 31.05.24
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a formal announcement dated June 28, 2024, from ABIVAX, detailing the 'Nombre d'actions composant le capital social et nombre total de droits de vote' (Number of shares comprising the share capital and total number of voting rights). It explicitly references compliance with French commercial code (Article L. 233-8 II) and AMF regulations (Article 223-16). This type of mandatory periodic disclosure regarding share capital structure and voting rights is a specific regulatory filing requirement in France, often related to changes in major shareholdings or general capital structure updates. Given the options, this is a notification about the capital structure and voting rights, which is a specific type of regulatory update. It is not a full report (10-K, IR), an earnings release (ER), or a dividend notice (DIV). It most closely aligns with a notification regarding share capital changes or major shareholding thresholds, but since it is a mandatory disclosure of the total voting rights count, it fits best under the general category for regulatory updates concerning ownership/capital structure. Since there isn't a perfect fit for 'Voting Rights Disclosure', and it is a formal regulatory filing updating key capital metrics, it falls under the general regulatory filing category (RNS) or potentially a specific capital/share announcement. However, the content is purely about the count of shares and voting rights, which is often required when crossing thresholds or periodically. Given the options, 'Major Shareholding Notification' (MRQ) is for *changes* in significant ownership, and 'Share Issue/Capital Change' (SHA) is for *actions* like splits or new issues. This document is a periodic statement of the current total rights. In the context of French regulations, this is a standard disclosure. Since it is a formal, periodic regulatory disclosure that doesn't fit the more specific categories like DIV, ER, or 10-K, the most appropriate general regulatory classification is RNS, although it is very close to SHA/MRQ contextually. Given the explicit focus on the total number of voting rights as required by AMF rules, and lacking a specific 'Voting Rights Disclosure' code, RNS (Regulatory Filings) serves as the best fit for this mandatory, non-periodic report announcement.
2024-06-28 French
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 30.04.24.
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a formal announcement dated May 29, 2024, titled 'Nombre d'actions composant le capital social et nombre total de droits de vote' (Number of shares comprising the share capital and total number of voting rights). It explicitly references compliance with French commercial code (Article L. 233-8 II) and AMF regulations (Article 223-16), providing a table detailing the number of shares and voting rights as of April 30, 2024. This type of periodic disclosure regarding the total number of shares and voting rights is a specific regulatory requirement in France, often related to capital structure transparency. While it touches upon capital structure, it is not a fundraising announcement (CAP) or a general share issue (SHA). It is a mandatory disclosure about the current capital structure and voting power, which fits best under the general regulatory disclosure category, or potentially a specific capital/share structure update. Given the options, this is a mandatory regulatory disclosure concerning the capital base, which is often reported alongside other capital changes or as a standalone transparency filing. Since it is a specific, recurring regulatory disclosure about the capital base and voting rights, and not a general 'Transaction in Own Shares' (POS) or 'Share Issue' (SHA), it is most appropriately classified as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) if interpreted broadly. However, since it is a mandatory, periodic disclosure of the capital structure details required by the AMF, and not a transaction announcement, RNS is the most appropriate fallback for specific regulatory transparency filings not covered elsewhere. Upon review, there is no specific code for 'Total Voting Rights Disclosure'. Therefore, RNS (General regulatory announcements) is the best fit for this mandatory AMF filing.
2024-05-29 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.